put take though second-quart perform solid overal
baxter report second-quart result revenu billion constant
currenc oper basi exclud foreign exchang gener competit
 cyclophosphamid clari acquisit roughli line
estim though adjust ep came estim
compani guidanc larg part beat driven incom
lower tax rate oper margin basi point street estim
full year manag increas guidanc adjust ep rang
growth roughli midpoint versu prior rang
prior estim baxter continu expect full-year sale growth
approxim constant currenc oper basi though
margin expect unchang
third quarter face tough comparison compani expect sale
growth approxim constant currenc oper basi impli
larg sequenti step-up fourth quarter meet full-year guidanc though note
easier fourth-quart comparison due hurrican headwind last year third-quart
adjust ep expect rang versu prior estim
stock trade time non-gaap ep estim
premium multipl peer put take quarter
includ come short street oper margin expectationsfundament perform
solid long-term perspect baxter focus put right piec
place strateg drive sustain top-lin growth improv gross margin
profil though still earli process realloc invest toward
profit geographi product categori creat volatil quarter
quarter believ chang take coupl year becom
materi result rate stock market perform
stock thought valuat
return equiti ttm
lead develop manufactur distributor wide varieti medic product
dialysi equip dispos servic intraven infus set solut
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
second-quart result second quarter revenu billion oper constant currenc line
guidanc estim growth quarter driven primarili inject pharmaceut renal care acut therapi
contract manufactur busi partli off-set weaker medic deliveri nutrit sale manag express
improv medic deliveri track slower anticip quarter believ challeng
short term natur believ issu short term lvp sound like improv quickli though other
may take time svp nutrit
medic deliveri nutrit perform expect respect medic
deliveri growth impact slower-than-anticip add new custom larg volum parenter
product lvp residu suppli constraint small volum parenter product svp lower intern sale
due realloc volum
baxter continu gain new lvp custom note taken larg oem custom competitor
remain confid outlook second half year said manag suggest compani abl
convert bed late quarter benefit effort quarter dynam sound like
improv rel quickli second-quart level
svp side baxter made slower improv continu see tight suppli work restor partner
back pre-hurrican level improv may take littl time manag believ end
year/earli svp alloc suggest better growth
nutrit suppli issu come hurrican despit strong sale outsid quarter
continu see delay custom return histor purchas pattern market team work
close custom manag confid busi also back cours though anticip requir
offset weak medic deliveri nutrit pharmaceut constant currenc
oper driven inject clari revenu million million
expect manag note pharmaceut benefit increment brevibloc revenu million ahead
expect part due competit suppli constraint manag also rais full-year guidanc cyclo
million sale quarter million million despit exist competit market anticip
increment competit enter market brevibloc septemb cyclo end year
bake guidanc
sale clari sale came baxter acquisit million quarter manag
continu anticip full-year contribut million believ perform track line expect
despit baxter receiv fda warn letter earlier month connect clari facil ahmedabad india
underw inspect day juli acquisit manag express current
expect warn letter materi impact long-rang target express may work correct
fda observ back-up plan place reason abl launch new molecul fast
advanc surgeri grew constant currenc million driven solid intern perform
acquisit recothrom preveleak togeth contribut million quarter forecast contribut
million full year increas demand contract manufactur servic new custom volum
sold exist also contribut growth help off-set declin medic deliveri nutrit segment
nice surpris upward remain focu compani
renal sale million constant currenc came line expect driven strong growth
pd therapi well intern hd busi new product launch may help growth
somewhat next year see detail
acut therapi constant currenc million line estim driven growth
continu strength world-wide crrt segment strong gross margin anoth area focus/growth baxter
margin expans gener adjust ep quarter came estim midpoint guidanc
though beat primarili driven lower tax rate benefit incom adjust oper margin
line estim though modestli street expect
margin expans key part stori investor compani expand oper margin
larg driven sg leverag manag see sg percentag revenu
potenti reach suggest continu leverag lesser pace prior year believ
remain room sg come view basi point next five
year difficult
believ gross margin improv compos major oper margin benefit expect come
next five year driven improv geograph mix launch higher-margin product pharmaceut medic
deliveri renal three area believ larger abil posit affect gross margin perform
three categori mix quarter pharmaceut ahead pace medic deliveri expect
renal line believ manag strategi place improv perform categori expect
effort might take quarter
compani tax rate came estim due million benefit stock compens guidanc
certain item settlement manag expect full-year tax rate similar quarter level
baxter strong cash flow one key long-term piec stori compani gener free cash flow
million first half million second quarter billion cash balanc
sheet estim full year manag expect gener free cash flow approxim billion
manag deploy cash balanc one key part stori next year two though
compani provid minim new commentari second-quart call manag remain commit well
abl handl deal size though continu believ like scenario smaller tuck-in
absenc believ compani continu evalu share repurchas dividend viabl sourc
capit alloc
guidanc full year baxter continu expect growth constant currenc oper growth
though report adjust one-tim million settlement compound custom third
quarter million tailwind hurrican fourth quarter impli larger step fourth quarter
rel third believ growth larg driven new product launch well recovery/new custom
medic deliveri bottom line manag increas expect full-year adjust ep rang
prior continu anticip oper margin expans basi point
impli adjust oper margin
new product launch believ baxter ultim remain track achiev target constant-curr
compound annual growth laid recent analyst day see note titl analyst day
expect strategi track improv mix larg driven commit product innov key product
medic deliveri compani recent launch process roll two new infus pump
believ sigma spectrum iq platform nice step-up compani new featur includ auto-
program auto-document integr two-way connect competit rel
peer allow baxter gain share though sale like lower margin capit placement begin
manag note platform convert one account number other line evo iq
pump addit repres baxter first new pump outsid year evo iq unit kingdom
australia new zealand ireland plan addit regulatori submiss intern
key product launch includ prismaflex japan prismax continu renal replac therapi
crrt monitor recent launch kaguya pd japan manag express kaguya pd track ahead
compani intern plan baxter acceler purchas product equip partner
japan abl suppli market believ under-penetrated roughli million million
pharmaceut front believ new high-margin molecul higher-margin gener inject
larg driver gross margin next half decad particularli repres third compani new product
revenu expect laid long-term plan said major drug across specialti care oncolog
cardiovascular anti-infect anesthesia launch latter half
model updat adjust estim base manag updat guidanc
sale model sale million constant currenc previous million constant
third quarter sale estim billion constant currenc previous billion
ep full year earn project previous
third quarter ep estim previous
sale model sale million constant currenc previous million
ep full year earn project previous
